135 related articles for article (PubMed ID: 36964084)
1. A randomized controlled trial of presatovir for respiratory syncytial virus after lung transplant.
Gottlieb J; Torres F; Haddad T; Dhillon G; Dilling DF; Knoop C; Rampolla R; Walia R; Ahya V; Kessler R; Budev M; Neurohr C; Glanville AR; Jordan R; Porter D; McKevitt M; German P; Guo Y; Chien JW; Watkins TR; Zamora MR
J Heart Lung Transplant; 2023 Jul; 42(7):908-916. PubMed ID: 36964084
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract.
Marty FM; Chemaly RF; Mullane KM; Lee DG; Hirsch HH; Small CB; Bergeron A; Shoham S; Ljungman P; Waghmare A; Blanchard E; Kim YJ; McKevitt M; Porter DP; Jordan R; Guo Y; German P; Boeckh M; Watkins TR; Chien JW; Dadwal SS
Clin Infect Dis; 2020 Dec; 71(11):2787-2795. PubMed ID: 31915807
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients.
Chemaly RF; Dadwal SS; Bergeron A; Ljungman P; Kim YJ; Cheng GS; Pipavath SN; Limaye AP; Blanchard E; Winston DJ; Stiff PJ; Zuckerman T; Lachance S; Rahav G; Small CB; Mullane KM; Patron RL; Lee DG; Hirsch HH; Waghmare A; McKevitt M; Jordan R; Guo Y; German P; Porter DP; Gossage DL; Watkins TR; Marty FM; Chien JW; Boeckh M
Clin Infect Dis; 2020 Dec; 71(11):2777-2786. PubMed ID: 31793991
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Drug Resistance during Phase 2b Clinical Trials of Presatovir in Adults Naturally Infected with Respiratory Syncytial Virus.
Porter DP; Guo Y; Perry J; Gossage DL; Watkins TR; Chien JW; Jordan R
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32071058
[TBL] [Abstract][Full Text] [Related]
5. Drug Resistance Assessment Following Administration of Respiratory Syncytial Virus (RSV) Fusion Inhibitor Presatovir to Participants Experimentally Infected With RSV.
Stray K; Perron M; Porter DP; Anderson F; Lewis SA; Perry J; Miller M; Cihlar T; DeVincenzo J; Chien JW; Jordan R
J Infect Dis; 2020 Oct; 222(9):1468-1477. PubMed ID: 31971597
[TBL] [Abstract][Full Text] [Related]
6. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial.
Cunningham S; Piedra PA; Martinon-Torres F; Szymanski H; Brackeva B; Dombrecht E; Detalle L; Fleurinck C;
Lancet Respir Med; 2021 Jan; 9(1):21-32. PubMed ID: 33002427
[TBL] [Abstract][Full Text] [Related]
7. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
DeVincenzo J; Tait D; Efthimiou J; Mori J; Kim YI; Thomas E; Wilson L; Harland R; Mathews N; Cockerill S; Powell K; Littler E
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712214
[TBL] [Abstract][Full Text] [Related]
8. A pilot phase 2a, randomized, double-blind, placebo-controlled study to explore the antiviral activity, clinical outcomes, safety, and tolerability of rilematovir at two dose levels in non-hospitalized adults with respiratory syncytial virus infection.
Nilsson AC; Pullman J; Napora P; Luz K; Gupta A; Draghi J; Guzman Romero AK; Aggarwal N; Petrova G; Ianus J; Vijgen L; Scott J; Sinha R; Rusch S; Huntjens D; Bertzos K; Stevens M;
Clin Microbiol Infect; 2023 Oct; 29(10):1320-1327. PubMed ID: 37422079
[TBL] [Abstract][Full Text] [Related]
9. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.
Liu V; Dhillon GS; Weill D
Transpl Infect Dis; 2010 Feb; 12(1):38-44. PubMed ID: 19761558
[TBL] [Abstract][Full Text] [Related]
10. CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus.
Ferrero F; Lin CY; Liese J; Luz K; Stoeva T; Nemeth A; Gijón M; Calvo C; Natalini S; Toh TH; Deleu S; Chen B; Rusch S; Sánchez BL; Leipoldt I; Vijgen L; Huntjens D; Baguet T; Bertzos K; Gamil M; Stevens M;
Paediatr Drugs; 2024 Jul; 26(4):411-427. PubMed ID: 38649595
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
12. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus.
Zamora MR; Budev M; Rolfe M; Gottlieb J; Humar A; Devincenzo J; Vaishnaw A; Cehelsky J; Albert G; Nochur S; Gollob JA; Glanville AR
Am J Respir Crit Care Med; 2011 Feb; 183(4):531-8. PubMed ID: 20851929
[TBL] [Abstract][Full Text] [Related]
13. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
Ramilo O; Lagos R; Sáez-Llorens X; Suzich J; Wang CK; Jensen KM; Harris BS; Losonsky GA; Griffin MP;
Pediatr Infect Dis J; 2014 Jul; 33(7):703-9. PubMed ID: 24356256
[TBL] [Abstract][Full Text] [Related]
14. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients.
Gottlieb J; Zamora MR; Hodges T; Musk AW; Sommerwerk U; Dilling D; Arcasoy S; DeVincenzo J; Karsten V; Shah S; Bettencourt BR; Cehelsky J; Nochur S; Gollob J; Vaishnaw A; Simon AR; Glanville AR
J Heart Lung Transplant; 2016 Feb; 35(2):213-21. PubMed ID: 26452996
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study.
Martinón-Torres F; Rusch S; Huntjens D; Remmerie B; Vingerhoets J; McFadyen K; Ferrero F; Baraldi E; Rojo P; Epalza C; Stevens M
Clin Infect Dis; 2020 Dec; 71(10):e594-e603. PubMed ID: 32201897
[TBL] [Abstract][Full Text] [Related]
16. EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge.
Ahmad A; Eze K; Noulin N; Horvathova V; Murray B; Baillet M; Grey L; Mori J; Adda N
N Engl J Med; 2022 Feb; 386(7):655-666. PubMed ID: 35172056
[TBL] [Abstract][Full Text] [Related]
17. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
Rodriguez WJ; Gruber WC; Welliver RC; Groothuis JR; Simoes EA; Meissner HC; Hemming VG; Hall CB; Lepow ML; Rosas AJ; Robertsen C; Kramer AA
Pediatrics; 1997 Mar; 99(3):454-61. PubMed ID: 9041304
[TBL] [Abstract][Full Text] [Related]
18. Incidence, management and outcome of respiratory syncytial virus infection in adult lung transplant recipients: a 9-year retrospective multicentre study.
Testaert H; Bouet M; Valour F; Gigandon A; Lafon ME; Philit F; Sénéchal A; Casalegno JS; Blanchard E; Le Pavec J; Ader F
Clin Microbiol Infect; 2021 Jun; 27(6):897-903. PubMed ID: 32827713
[TBL] [Abstract][Full Text] [Related]
19. Antiviral Efficacy of a Respiratory Syncytial Virus (RSV) Fusion Inhibitor in a Bovine Model of RSV Infection.
Jordan R; Shao M; Mackman RL; Perron M; Cihlar T; Lewis SA; Eisenberg EJ; Carey A; Strickley RG; Chien JW; Anderson ML; McEligot HA; Behrens NE; Gershwin LJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4889-900. PubMed ID: 26055364
[TBL] [Abstract][Full Text] [Related]
20. Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.
Stevens M; Rusch S; DeVincenzo J; Kim YI; Harrison L; Meals EA; Boyers A; Fok-Seang J; Huntjens D; Lounis N; Mari N K; Remmerie B; Roymans D; Koul A; Verloes R
J Infect Dis; 2018 Jul; 218(5):748-756. PubMed ID: 29684148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
